drugset / Trial / NCT00511992
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.
Timeline
- Start
- 2007-07
- Primary completion
- 2015-08-03
- Completion
- 2015-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |